The angiotensin converting enzyme inhibitor, captopril, prevents the hyperactivity and impulsivity of neurokinin-1 receptor gene 'knockout' mice: Sex differences and implications for the treatment of attention deficit hyperactivity disorder

European Neuropsychopharmacology

Volumn 25, Issue 4, 2015, Pages 512-521

  Porter, Ashley J ^a   Pillidge, Katharine ^a   Grabowska, Ewelina M ^a   Stanford, S Clare ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

ADHD; Angiotensin receptor; Captopril; Hyperactivity; Impulsivity; Neurokinin 1 receptor

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; CAPTOPRIL; LOSARTAN; NEUROKININ 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATTENTION DEFICIT DISORDER; COGNITION; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; ENZYME INHIBITION; FEMALE; GENOTYPE; IMPULSIVENESS; KNOCKOUT GENE; LOCOMOTION; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; REACTION TIME; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SEX DIFFERENCE; TASK PERFORMANCE; WILD TYPE; ANALYSIS OF VARIANCE; ANIMAL; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; C57BL MOUSE; DECISION MAKING; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; GENETICS; HYPERKINESIS; KNOCKOUT MOUSE; MOTOR ACTIVITY; SEX DIFFERENTIATION;

ANALYSIS OF VARIANCE; ANGIOTENSIN II TYPE 2 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CAPTOPRIL; CHOICE BEHAVIOR; DISEASE MODELS, ANIMAL; FEMALE; HYPERKINESIS; IMIDAZOLES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; PYRIDINES; REACTION TIME; RECEPTORS, NEUROKININ-1; SEX DIFFERENTIATION;

EID: 84928212918     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2015.01.013     Document Type: Article

References (49)

1. Allen A.M., MacGregor D.P., Chai S.Y., Donnan G.A., Kaczmarczsyk S.J., Richardson K., Kalnins R.M., Ireton J., Mendelsohn F.A.O. Angiotensin II receptor binding associated with nigro-striatal dopaminergic neurons in human basal ganglia. Ann. Neurol. 1992, 32:339-344.
2. Anderson S.L., Teicher M.H. Sex differences in dopamine receptors and their relevance to ADHD. Neurosci. Biobehav. Rev. 2000, 24:137-141.
3. Aston-Jones G., Cohen J.D. Adaptive gain and the role of the locus coeruleus-norepinephrine system in optimal performance. J. Comp. Neurol. 2005, 493:99-110.
4. Barnes J.M., Barnes N.M., Costall B., Coughlan J., Kelly M.E., Naylor R.J., Tomkins D.M., Williams T.J. Angiotensin-converting enzyme inhibition, angiotensin, and cognition. J. Cardiovasc. Pharmacol. 1992, 19:S63-S71.
5. Braszko J.J. AT(2) but not AT(1) receptor antagonism abolishes angiotensin II increase of the acquisition of conditioned avoidance responses in rats. Behav. Brain Res. 2002, 131:79-86.
6. Chai S.Y., Mendelsohn F.A., Paxinos G. Angiotensin converting enzyme in rat brain visualised by quantitative in vitro autoradiography. Neuroscience 1987, 20:615-627.
7. Clark R.A., Shoaib M., Hewitt K.N., Stanford S.C., Bate S.T. A comparison of InVivoStat with other statistical software packages for analysis of data generated from animal experiments. J. Psychopharmacol. 2012, 26:1136-1142.
8. Croog S.H., Levine S., Testa M.A., Brown B., Bulpitt C.J., Jenkins C.D., Klerman G.L., Williams G.H. The effects of antihypertensive therapy on the quality of life. N. Engl. J. Med. 1986, 314:1657-1664.
9. Currie D., Lewis R.V., McDevitt D.G., Nicholson A.N., Wright N.A. Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood. Br. J. Clin. Pharmacol. 1990, 30:527-536.
10. De Felipe C., Herrero J.F., O'Brien J.A., Palmer J.A., Doyle C.A., Smith A.J, Laird J.M., Belmonte C., Cervero F., Hunt S.P. Altered nociception, analgesia and aggression in mice lacking the receptor for substance P. Nature 1998, 8060:394-397.
11. Del Campo N., Chamberlain S.R., Sahakian B.J., Robbins T.W. The roles of dopamine and noradrenaline in the pathophysiology and treatment of attention-deficit/hyperactivity disorder. Biol. Psychiatry. 2011, 69:e145-e157.
12. Dudley J.A., Weir R.K., Yan T.C., Grabowska E.M., Grimmé A.J., Amini S., Stephens D.N., Hunt S.P., Stanford S.C. Antagonism of L-type Ca(v) channels with nifedipine differentially affects performance of wildtype and NK1R-/- mice in the 5-choice serial reaction-time task. Neuropharmacology 2013, 64:329-336.
13. Earley B., Burke M., Leonard B.E. Effects of captopril on locomotor activity, passive avoidance behaviour and spatial memory tasks in the trimethyltin-treated rat. Neuropsychobiology 1989, 22:49-56.
14. Fisher A.S., Stewart R.J., Yan T., Hunt S.P., Stanford S.C. Disruption of noradrenergic transmission and the behavioural response to a novel environment in NK1R-/- mice. Eur. J. Neurosci. 2007, 25:1195-1204.
15. Geppetti P., Spillantini M.G., Frilli S., Pietrini U., Fanciullacci M., Sicuteri F. Acute oral captopril inhibits angiotensin converting enzyme activity in human cerebrospinal fluid. J. Hypertens. 1987, 5:151-154.
16. Haaxma C.A., Bloem B.R., Borm G.F., Oyen W.J., Leenders K.L., Eshuis S., Booij J., Dluzen D.E., Horstink M.W. Gender differences in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 2007, 78:819-824.
17. Herpfer I., Hunt S.P., Stanford S.C. A comparison of neurokinin 1 receptor knock-out (NK1-/-) and wildtype mice: exploratory behaviour and extracellular noradrenaline concentration in the cerebral cortex of anaesthetised subjects. Neuropharmacology 2005, 48:706-719.
18. Irvine R.J., White J.M., Head R.J. The renin angiotensin system and nociception in spontaneously hypertensive rats. Life Sci. 1995, 56:1073-1078.
19. Jenkins T.A. Effect of angiotensin-related antihypertensives on brain neurotransmitter levels in rats. Neurosci. Lett. 2008, 444:186-189.
20. Komukai K., Mochizuki S., Yoshimura M. Gender and the renin-angiotensin-aldosterone system. Fund. Clin. Pharmacol. 2010, 24:687-698.
21. Macova M., Pavel J., Saavedra J.M. A peripherally administered, centrally acting angiotensin II AT2 antagonist selectively increases brain AT1 receptors and decreases brain tyrosine hydroxylase transcription, pituitary vasopressin and ACTH. Brain Res. 2009, 1250:130-140.
22. Michael-Titus A.T., Fernandes K., Setty H., Whelpton R. In vivo metabolism and clearance of substance P and co-expressed tachykinins in rat striatum. Neuroscience 2002, 110:277-286.
23. Mitchell A.J., Lone A.M., Tinoco A.D., Saghatelian A. Proteolysis controls endogenous substance P levels. PLoS One 2013, 19:e68638.
24. Mondadori C., Etienne P. Nootropic effects of ACE inhibitors in mice. Psychopharmacology 1990, 100:301-307.
25. Nikolova J.G., Getova D.P., Nikolov F.P. Effects of ACE-inhibitors on learning and memory processes in rats. Folia Med. (Plovdiv.) 2000, 42:47-51.
26. Oades R.D. Dopamine may be 'hyper' with respect to noradrenaline metabolism, but 'hypo' with respect to serotonin metabolism in children with attention-deficit hyperactivity disorder. Behav. Brain Res. 2002, 130:97-102.
27. Oblin A., Danse M.J., Zivkovic B. Degradation of substance P by membrane peptidases in the rat substantia nigra: effect of selective inhibitors. Neurosci. Lett. 1988, 84:91-96.
28. Pillidge K., Porter A.J., Dudley J.A., Tsai Y.C., Heal D.J., Stanford S.C. The behavoural response of mice lacking NK1 receptors to guanfacine resembles its clinical profile in treatment of ADHD. Br. J. Pharmacol. 2014, 171:4785-4796.
29. Prus A.J., Huang M., Li Z., Dai J., Meltzer H.Y. The neurotensin analog NT69L enhances medial prefrontal cortical dopamine and acetylcholine efflux: potentiation of risperidone-, but not haloperidol-, induced dopamine efflux. Brain Res. 2007, 1183:354-364.
30. Raghavendra V., Chopra K., Kulkarni S.K. Modulation of motor functions involving the dopaminergic system by AT1 receptor antagonist, losartan. Neuropeptides 1998, 32:275-280.
31. Raghavendra V., Chopra K., Kulkarni S.K. Comparative studies on the memory-enhancing actions of captopril and losartan in mice using inhibitory shock avoidance paradigm. Neuropeptides 2001, 35:65-69.
32. Ranadive S.A., Chen A.X., Serajuddin A.T. Relative lipophilicities and structural-pharmacological considerations of various angiotensin-converting enzyme (ACE) inhibitors. Pharm. Res. 1992, 9:1480-1486.
33. Reid M.S., Herrera-Marschitz M., Terenius L., Ungerstedt U. Intranigral substance P modulation of striatal dopamine: interaction with N-terminal and C-terminal substance P fragments. Brain Res. 1990, 526:228-234.
34. Rozzini L., Chilovi B.V., Bertoletti E., Conti M., Del Rio I., Trabucchi M., Padovani A. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int. J. Geriatr. Psychiatry 2006, 21:550-555.
35. Rubia K., Smith A., Taylor E. Performance of children with attention deficit hyperactivity disorder (ADHD) on a test battery of impulsiveness. Child Neuropsychol. 2007, 13:276-304.
36. Rucklidge J.J. Gender differences in attention-deficit/hyperactivity disorder. Psychiatr. Clin. North Am. 2010, 33:357-373.
37. Sharp S.I., McQuillin A., Marks M., Hunt S.P., Stanford S.C., Lydall G.J., Morgan M.Y., Asherson P., Curtis D., Gurling H.M. Genetic association of the tachykinin receptor 1 TACR1 gene in bipolar disorder, attention deficit hyperactivity disorder, and the alcohol dependence syndrome. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2014, 165B:373-380.
38. Shulman L.M. Gender differences in Parkinson's disease. Gend. Med. 2007, 4:8-18.
39. Skidgel R.A., Engelbrecht S., Johnson A.R., Erdös E.G. Hydrolysis of substance p and neurotensin by converting enzyme and neutral endopeptidase. Peptides 1984, 5:769-776.
40. 2+ channels and implications for the treatment of ADHD. Neuropharmacol 2014, 87:9-18.
41. Staller J., Faraone S.V. Attention-deficit hyperactivity disorder in girls: epidemiology and management. CNS Drugs 2006, 20:107-123.
42. Strittmatter S.M., Lo M.M., Javitch J.A., Snyder S.H. Autoradiographic visualization of angiotensin-converting enzyme in rat brain with [3H]captopril: localization to a striatonigral pathway. Proc. Natl. Acad. Sci. U.S.A. 1984, 81:1599-1603.
43. Sumners C., Phillips M.I. Central injection of angiotensin II alters catecholamine activity in rat brain. Am. J. Physiol. 1983, 244:R257-R263.
44. Tannock R., Schacher R., Logan G. Methylphenidate and cognitive flexibility: dissociated dose effects in hyperactive children. J. Abnorm. Child Psychol. 1995, 23:235-267.
45. Vijayapandi P., Nagappa A.N. Biphasic effects of losartan potassium on immobility in mice. Yakugaku Zasshi 2005, 125:653-657.
46. Waddell J., McCarthy M.M. Sexual differentiation of the brain and ADHD: what is a sex difference in prevalence telling us?. Behavioural Neuroscience of Attention Deficit Hyperactivity Disorder 2012, 341-360. Springer-Verlag. C. Stanford, R. Tannock (Eds.).
47. Wright J.W., Harding J.W. Brain renin-angiotensin-a new look at an old system. Prog. Neurobiol. 2011, 95:49-67.
48. Yan T.C., McQuillin A., Thapar A., Asherson P., Hunt S.P., Stanford S.C., Gurling H. NK1 (TACR1) receptor gene 'knockout' mouse phenotype predicts genetic association with ADHD. J. Psychopharmacol. 2010, 24:27-38.
49. Yan T.C., Dudley J.A., Weir R.K., Grabowska E.M., Peña-Oliver Y., Ripley T.L., Hunt S.P., Stephens D.N., Stanford S.C. Performance deficits of NK1 receptor knockout mice in the 5-choice serial reaction-time task: effects of d-amphetamine, stress and time of day. PLoS One 2011, 6:e17586.